Vasculopathy and Increased Vascular Congestion in Fatal COVID-19 and Acute Respiratory Distress Syndrome

Julian A. Villalba1,2,†, Caroline F. Hilburn1,2,‡, Michelle A. Garlin3,4, Grant A. Elliott5, Yijia Li6, Keiko Kunitoki7,8, Sergio Poli9, George A. Alba10, Emilio Madrigal1–2, Manuel Taso11, Melissa C. Price12, Alexis J. Aviles1, Milagros Araujo-Medina1,13, Liana Bonanno1,12, Baris Boyraz1,2, Samantha N. Champion1,2,14,15, Cynthia K. Harris1,2, Timothy L. Helland1,2, Bailey Hutchison1,2, Soma Jobbagy1,2, Michael S. Marshall1,2, Daniel J. Shepherd1,2, Jaimie L. Barth1, Yin P. Hung1,2, Amy Ly1,2, Lida P. Harii1,2,10, Sarah E. Turbett1,2,16, Virginia M. Pierce1,2,17, John A. Branda1,2, Eric S. Rosenberg1,2,18, Javier Mendez-Pena1, Ivan Chebib1,2, Ivy A. Rosales1,2,13, Rex N. Smith1,2,13, Miles A. Miller3, Ivan O. Rosas18, Charles C. Hardin10, Lindsey R. Baden6, Benjamin D. Medoff10, Robert B. Colvin1,2,13, Brent P. Little12,19, James R. Stone1,2, Mitia Mino-Kenudson1,2, and Angela R. Shih1,25

1James Homer Wright Pathology Laboratories, 2Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts; 3Department of Pathology, Harvard Medical School, Boston, Massachusetts; 4Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York; 5Unboxed Systems LLC, West Palm Beach, Florida; 6Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; 7Harvard T. H. Chan School of Public Health, Boston, Massachusetts; 8Department of Psychiatry; 9Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mount Sinai Medical Center, Miami Beach, Florida; 10Division of Thoracic Imaging and Intervention, Department of Radiology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts; 11Division of Pulmonary and Critical Care Medicine, Department of Medicine, Boston, Massachusetts; 12Division of Thoracic Imaging and Intervention, Department of Radiology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts; 13Immunopathology Research Laboratory, and 16Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; 14Department of Medicine, Mount Sinai Medical Center, Miami Beach, Florida; 15Division of MRI Research, Department of Radiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts; 16Pediatric Infectious Disease Unit, Massachusetts General Hospital for Children, Boston, Massachusetts; 17Immunology Research Laboratory, and 18Division of Cardiothoracic Imaging, Department of Radiology, Mayo Clinic Florida, Jacksonville, Florida

Abstract

Rationale: The leading cause of death in coronavirus disease 2019 (COVID-19) is severe pneumonia, with many patients developing acute respiratory distress syndrome (ARDS) and diffuse alveolar damage (DAD). Whether DAD in fatal COVID-19 is distinct from other causes of DAD remains unknown.

Objective: To compare lung parenchymal and vascular alterations between patients with fatal COVID-19 pneumonia and other DAD-causing etiologies using a multidimensional approach.

Methods: This autopsy cohort consisted of consecutive patients with COVID-19 pneumonia (n = 20) and with respiratory failure and histologic DAD (n = 21; non–COVID-19 viral and nonviral etiologies). Premortem chest computed tomography (CT) scans were evaluated for vascular changes. Postmortem lung tissues were compared using histopathological and computational analyses. Machine-learning-derived morphometric analysis of the microvasculature was performed, with a random forest classifier quantifying vascular congestion (C\text{Vasc}) in different microscopic compartments. Respiratory mechanics and gas-exchange parameters were evaluated longitudinally in patients with ARDS.

Measurements and Main Results: In premortem CT, patients with COVID-19 showed more dilated vasculature when all lung segments were evaluated (P = 0.001) compared with controls with DAD. Histopathology revealed vasculopathic changes, including hemangiomatosis-like changes (P = 0.043), thromboemboli (P = 0.0038), pulmonary infarcts (P = 0.047), and perivascular inflammation (P < 0.001). Generalized estimating equations revealed significant regional differences in the lung microarchitecture among all DAD-causing entities. COVID-19 showed a larger overall C\text{Vasc} range (P = 0.002). Alveolar-septal congestion was associated with a significantly shorter time to death from symptom onset (P = 0.03), length of hospital stay (P = 0.02), and increased ventilatory ratio [an estimate for pulmonary dead space fraction (V\text{d}); p = 0.043] in all cases of ARDS.

Conclusions: Severe COVID-19 pneumonia is characterized by significant vasculopathy and aberrant alveolar-septal congestion. Our findings also highlight the role that vascular alterations may play in V\text{d} and clinical outcomes in ARDS in general.

Keywords: COVID-19; ARDS; vasculopathy; vascular congestion; ventilatory ratio
Coronavirus disease 2019 (COVID-19), caused by infection with the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has a wide range of clinical manifestations from asymptomatic states to fulminant disease (1). Patients with severe pneumonia can present with acute respiratory distress syndrome (ARDS) and multigorgan dysfunction (2). Several recent descriptive autopsy reports of patients with COVID-19 have identified diffuse alveolar damage (DAD) in over 90% of cases, which appears comparable with the proportion of patients with DAD in other fatal viral infections (3).

Traditional histopathological studies have suggested that DAD caused by COVID-19 appears to be associated with increased microthrombi (4) but is otherwise indistinguishable from DAD due to other causes (3–5). However, a comprehensive, integrative, and quantitative understanding of the effect of SARS-CoV-2 in the lung, particularly the pulmonary vasculature, is still lacking. Here, we use combined radiological, histopathological, and computational analyses (Figure 1) to examine the morphological features and spatial architecture and correlate them with respiratory mechanics and gas-exchange parameters in fatal COVID-19 pneumonia in comparison with other viral and nonviral etiologies of DAD.

Methods

Study Design and Participants
Twenty consecutive autopsies of patients who died after SARS-CoV-2 infection were performed at the Massachusetts General Hospital in Boston during the peak of the initial COVID-19 surge (March 30, 2020–May 7, 2020). The study was approved by the hospital’s institutional review board. Written informed consent for the autopsy was obtained from next of kin or healthcare proxy as appropriate for all patients. Inclusion criteria included a confirmed diagnosis of SARS-CoV-2 infection by nucleic acid testing on premortem nasopharyngeal swab, along with postmortem assessment confirming COVID-19 as the primary cause of death.

Additionally, a control set of 21 prepandemic autopsies of non–COVID-19 patients with lethal respiratory failure and histologic evidence of DAD was identified for comparison. Of these non–COVID-19 DAD controls, 14 showed DAD of nonviral etiologies, and seven showed DAD from viral infections. Exclusion criteria for all cases included the presence of known preexisting underlying fibrotic interstitial lung disease and age <18 years old. We also excluded cases of primary nonsystemic bacterial or fungal pneumonia, as these tend to have a more neutrophilic/abscess-type histopathological morphology, which is distinct from both virus-associated DAD (including COVID-19–related) and noninfectious etiologies of DAD. Clinical information was obtained from the electronic medical record. Further details, including the etiologies of the non–COVID-19 DAD controls are described in the online supplement (Supplemental Methods; Table E1).

Procedures

Chest imaging. Chest computed tomography (CT) examinations were performed on a subset of patients for routine clinical care, with a slice thickness of 1.25 mm according to standard clinical protocols, and reviewed by a thoracic radiologist blinded to clinical and pathological data. Each segment of the five lung lobes was evaluated for dilated segmental or subsegmental vessels, with a nonseverity score based on the distribution of the vessels as follows: 0 = no dilated vessels, 1 = either dilated peripheral or central vessels, and 2 = dilated central and peripheral vessels. We also calculated a global dilated vessel score, which incorporates information on all the lung segments and is the result of adding all the individual segmental vessel scores in each patient. In addition, lung involvement by mosaic attenuation, ground-glass, or consolidative opacities was...
Histology. Lung tissue from patients with COVID-19 was obtained from autopsies completed under a standardized protocol following CDC guidelines (Supplemental Methods; Figure E1). A total of 50 lung formalin-fixed paraffin-embedded tissue blocks per patient were processed and assessed with routine hematoxylin and eosin (H&E)-stained slides. Each H&E-stained slide was semiquantitatively scored for a variety of histologic features by two pulmonary pathologists blinded to clinical and radiological data (Table E2).

Morphometric analysis. From each autopsy, two H&E-stained lung slides were selected by a pathologist and scanned under 80× optical magnification at approximately 8,200 pixels per micron. A random forest classifier was trained and used to label every pixel in each scanned image as belonging in one of three categories: stroma, red blood cell (RBC), or air (Figure 2A; Figures E2–E4). Of note, the classifier does not distinguish between different types of stromal tissue present. Analyses were performed within QuPath (6), which uses the OpenCV library for pixel classification. Regions of interest (ROI) were manually selected by two pathologists using QuPath’s annotation tools and included cartilaginous airways, noncartilaginous airways, and alveolar septa (intra-alveolar space was excluded). The final classification was applied within ROI to produce detailed quantitative measurements within microarchitectural compartments, such that one classifier was used throughout (Figure E5). For example, bronchiolar stroma was defined by pixels designated as stroma within a manually annotated bronchiolar structure. Of note, annotations were not performed within areas of lung infarction and necrosis, areas with extensive intra-alveolar hemorrhage or inflammation, areas of fibrosis, or areas in which the lung microarchitecture was severely disrupted.

After microarchitectural segmentation, quantitative data of the classification in ROI were used for morphometrical determination of the vascular congestion ($C_{Vasc}$), which represents the proportion of surface area occupied by (dilated) vascular lumina in specific compartments of the lung parenchyma, defined as:

$$C_{Vasc} = \frac{RBC_{pix}}{(RBC_{pix} + Stromata_{pix})} \times 100$$

Where $RBC_{pix}$ and $Stromata_{pix}$ are equal to RBC and stroma pixels, respectively.

Morphometric data were obtained from all the ROI manually annotated in whole slide images (WSIs) representing highly and minimally congested regions of the lung parenchyma (Figure 2B). Morphometric data were classified as “intralobe” when obtained within a single WSI and as “interslide” when obtained from all WSIs of each patient. From each autopsy, we also separately designated one individual annotation with the highest $C_{Vasc}$ (interslide-Max$C_{Vasc}$) and the lowest $C_{Vasc}$ (interslide-Min$C_{Vasc}$) within each microarchitectural compartment. We calculated the interslide-alveolar-septal $C_{Vasc}$ range (interslide-alveolar $\Delta_{Congestion}$) as follows:

$$\Delta_{Congestion} = (MaxC_{Vasc} - MinC_{Vasc})$$

Of note, the interslide-alveolar $\Delta_{Congestion}$ likely reflects the heterogeneity of alveolar-septal $C_{Vasc}$ at the macroscopic level.

We also calculated the arithmetic mean $C_{Vasc}$ (AM-alveolar $C_{Vasc}$) per case, which is equal to the average alveolar $C_{Vasc}$ value of all manual alveolar-septal annotations per autopsy. Therefore, only one value of AM-alveolar $C_{Vasc}$ is generated per autopsy case. Further details of the morphometric analyses are described in the Supplemental Methods.

Pathophysiology in ARDS. BERLIN DEFINITION. We retrospectively categorized patients with ARDS by the Berlin Definition (7). Data for categorization were obtained within 24 hours of initiation of invasive mechanical ventilation. Cases were assessed for ARDS by a physician certified in pulmonary disease and critical care medicine.

Respiratory mechanics and gas-exchange parameters. Electronic medical records of patients with ARDS were reviewed for demographic, clinical, and gas-exchange laboratory variables. Hourly data of respiratory mechanics in the last 72 hours before death were also obtained. Gas-exchange laboratory data obtained included: arterial partial pressure of oxygen ($P_{A,O_2}$), arterial oxygen saturation ($S_{A,O_2}$), spot oxygen saturation ($S_{P,O_2}$), partial pressure of carbon dioxide ($P_{A,CO_2}$), arterial pH, and arterial bicarbonate. Respiratory mechanics data obtained included: the fraction of inspired oxygen ($F_{I,O_2}$), positive end-expiratory pressure (PEEP), peak inspiratory pressure, peak expiratory pressure, and minute ventilation.
the SpO2/FIO2 ratio, lung static compliance described in the Supplemental Methods.

to calculate these other parameters are power. Further details and the formulas used (Crs), driving pressure, and mechanical ventilation, and respiratory rate.

We used the ventilatory ratio (VR) as a simple surrogate for directly measured pulmonary physiological dead space fraction (Vd/Q), as it can be calculated at the bedside (8, 9) by comparing actual measurements of minute ventilation and PaCO2, with predicted values of minute ventilation and PaCO2, as defined by the following equation:

\[
VR_{exhaled} = \frac{(\text{Minute Ventilation}_{\text{act}}/\text{min} \times \text{PaCO}_2,\text{mmHg})}{(\text{Predicted Body Weight}_{\text{kg}} \times 100 \times 37.5)}
\]

We also calculated other parameters in each patient, including the PaO2/FIO2 ratio, the SpO2/FIO2 ratio, lung static compliance (Crs), driving pressure, and mechanical power. Further details and the formulas used to calculate these other parameters are described in the Supplemental Methods.

**Statistical analyses.** Analyses were performed using R (version 4.1.2), Python SciPy v.1.4.1, JMP 16.0 (SAS Institute Inc.), and GraphPad Prism 7.0 (GraphPad Software, Inc.). Further statistical details are described in the Supplemental Methods.

**Results**

Demographic and clinical characteristics of all patients are presented in Table 1. There were no significant differences in sex, age, body mass index (BMI), place of death, time to death from symptom onset, immunosuppression, anticoagulant or immunosuppressive therapy, and renal replacement therapy between patients with COVID-19 and non–COVID-19 DAD controls. No significant differences in premortem hematocrit values were seen between patients with COVID-19 and controls with DAD (P = 0.091; Figure E6).

The number of patients meeting the Berlin Definition for ARDS (7) was not statistically different between patients with COVID-19 and non–COVID-19 DAD controls (P = 0.17), and among those, there were no significant differences in hypoxemia severity within 24 hours of intubation. Patients with COVID-19 had a significantly shorter hospital stay (P = 0.039) and were less likely to be mechanically ventilated than non–COVID-19 DAD controls (P = 0.0034). However, all patients with severe COVID-19 pneumonia (n = 4) who were not mechanically ventilated because of goals of care (do-not-intubate orders) had mild-to-severe hypoxemia and showed pathologic evidence of DAD. Other relevant clinical characteristics and laboratory values are listed in the online supplement (Supplemental Results; Tables E3 and E4).
pulmonary vessel scores of patients with COVID-19 and controls with DAD (Figures 3B and 3C). Additionally, patients with COVID-19 exhibited statistically significant higher mean dilated vessel scores compared with controls with non–COVID-19 DAD (Figure 3D; P = 0.001). The global dilated vessel score was also significantly higher in patients with COVID-19 compared with controls with non–COVID-19 DAD (Figure 3E; patients with COVID-19: 13.5 ± 4.0, controls with DAD: 3.6 ± 2.4, P = 0.001).

Among other imaging features, mosaic attenuation in areas of apparently normal lung parenchyma on a conventional chest CT lung window (Hounsfield units: −500 to 1,000) was also more extensive in patients with COVID-19 compared with that in non–COVID-19 DAD controls when evaluated by a semiquantitative scoring system (P < 0.02; Supplemental Results; Figures E7 and E8). Notably, cardiac measurements on CT imaging (Figure E9) or echocardiogram did not differ significantly between patients with COVID-19 and non–COVID-19 DAD controls (Table E6).

**Histologic Findings**

Full histologic details are shown in Table 2 and in the Supplemental Results. Overall histologic assessment indicated that all patients with COVID-19 had features of DAD, with most of them (13/20) having features of mixed acute and organizing DAD. Aggregate measurements over each lung lobe showed bilateral disease in 19 (95%) patients and at least focal involvement of all lobes in 17 (85%) patients. Similarly, controls with viral DAD showed extensive and diffuse findings across all lobes, but controls with non–viral DAD showed more patchy/focal involvement. No disease group differences in DAD stage were found (P = 0.42).

Most patients with COVID-19 showed multiple intra-alveolar processes, including: hyaline membranes (n = 19/20), reactive pneumocytes (n = 19/20), intra-alveolar giant cells (n = 11/20), accumulation of intra-alveolar macrophages (n = 19/20), alveolar hemorrhage (n = 14/20), and alveolar edema (n = 16/20). The controls with non–COVID-19 DAD showed similar degrees of most of these histologic features, but with a significant decrease in alveolar edema (controls with non–viral DAD: P = 0.001; controls with viral DAD: P = 0.002; overall: P < 0.001; Figure 4A). Additionally,
Two-group comparisons were performed between patients with COVID-19 and all controls with non–COVID-19 DAD.

Multigroup comparisons were performed between patients with COVID-19, patients with non-viral DAD, and controls with viral DAD.

### Table 1. Patient Characteristics

|                      | Patients with COVID-19 (n = 20) | All (n = 21) | Non-Viral DAD (n = 14) | Viral DAD (n = 7) | P Value |
|----------------------|---------------------------------|-------------|-----------------------|-----------------|---------|
|                      |                                 |             |                       |                 |         |
| **Demographics**     |                                 |             |                       |                 |         |
| Sex, ratio (men:women) | 1.5:1                           | 1.6:1       | 1.3:1                 | 2.5:1           | 0.55    |
| Age, mean (± SD)     | 64.1 (± 19.3)                   | 53.3 (± 19.0) | 57.3 (± 17.3)         | 45.1 (± 20.8)   | 0.10    |
| BMI, in kg/m², mean (± SD) | 34.5 (± 9.2)                   | 30.2 (± 6.5) | 29.4 (± 6.6)          | 32.0 (± 6.1)    | 0.11    |
| **Place of death, n (%)** | 17 (85)                        | 21 (100)    | 14 (100)              | 7 (100)         | 0.11    |
| Hospital             |                                 |             |                       |                 |         |
| Extended care facility | 3 (15)                         | 0 (0)       | 0 (0)                 | 0 (0)           | 0.11    |
| **Clinical outcomes**|                                 |             |                       |                 |         |
| Hospital stay, in days, mean (± SD) | 8.2 (± 5.2)                | 14.4 (± 10.6) | 15.9 (± 9.4)         | 11.6 (± 10)    | 0.039   |
| Time to death from symptom onset, in days, mean (± SD) | 13.9 (± 7.7)                | 20.0 (± 16.6) | 20.1 (± 12.0)        | 19.7 (± 18.7)  | 0.17    |
| ICU admission, n (%)  | 13 (76)                         | 20 (100)    | 13 (100)              | 7 (100)         | 0.04    |
| **Clinical characteristics, n (%)** |                                 |             |                       |                 |         |
| Meets Berlin Definition for ARDS | 11 (65)                      | 16 (80)     | 11 (85)               | 5 (71)          | 0.17    |
| Severe pneumonia/ARDS** | 4 (24)                        | 0 (0)       | 0 (0)                 | 0 (0)           | 0.02    |
| **Ventilatory support**|                                 |             |                       |                 |         |
| Invasive mechanical ventilation, n (%) | 13 (76)                     | 20 (100)    | 13 (100)              | 7 (100)         | 0.01    |
| Intubation length, mean (± SD) | 7.2 (± 4.9)                | 8.2 (± 8.5) | 8.1 (± 7.1)          | 8.3 (± 11.3)   | 0.92    |
| ECMO, n (%) | 1 (5) | 3 (14) | 1 (8) | 2 (29) | 0.60 |
| **ARDS patients**    |                                 |             |                       |                 |         |
| Nadir, PaO₂/FiO₂ within 24 h of intubation, mean (± SD) | 139.2 (± 73)     | 127.5 (± 63)  | 147 (± 66.7)         | 84.6 (14.4)   | 0.67    |
| Hypoxemia severity within 24 h of intubation, n (%) | 0.81 | 0.28 |
| **Mild** | | | | | |
| PaO₂/FiO₂, 201–300 mm Hg | 3 (27) | 3 (19) | 3 (27) | 0 (0) | |
| SpO₂/FiO₂, 236–315 mm Hg | | | | | |
| **Moderate** | | | | | |
| PaO₂/FiO₂, 101–200 mm Hg | 3 (27) | 6 (38) | 5 (46) | 1 (20) | |
| SpO₂/FiO₂, 151–235 mm Hg | | | | | |
| **Severe** | | | | | |
| PaO₂/FiO₂, <100 mm Hg | 5 (46) | 7 (44) | 3 (27) | 4 (80) | |
| SpO₂/FiO₂, <150 mm Hg | | | | | |
| **Immunocompromised states, n (%)** | | | | | |
| Any immunosuppression | 6 (30) | 10 (50) | 7 (54) | 3 (43) | 0.33 |
| Connective tissue or autoimmune disorders | 5 (25) | 5 (25) | 2 (15) | 3 (43) | 1.0 |
| Transplantation, n (%) | | | | | |
| Hematopoietic cell | 0 (0) | 3 (15) | 3 (23) | 0 (0) | 0.23 |
| Solid organ | 1 (5) | 1 (5) | 0 (0) | 1 (14) | 1.0 |
| HIV infection | 0 (0) | 1 (5) | 1 (8) | 0 (0) | 1.0 |
| Treatments, n (%) | | | | | |
| Anticoagulant agents | | | | | |
| Not in anticoagulation | 5 (25) | 5 (25) | 3 (23) | 2 (29) | 1.0 |
| Prophylactic dose | 9 (45) | 4 (20) | 4 (31) | 0 (0) | 0.18 |
| Treatment dose | 6 (30) | 11 (55) | 6 (28) | 5 (71) | 0.20 |
| Immunosuppressive therapy | | | | | |
| Any therapy | 14 (70) | 14 (70) | 9 (69) | 5 (71) | 1.0 |
| Corticosteroids | 9 (45) | 14 (70) | 9 (69) | 5 (71) | 0.20 |
| Immune modulators | 14 (70) | 7 (35) | 4 (31) | 3 (43) | 0.056 |
| Other treatments | | | | | |
| Renal replacement therapy | 4 (24) | 10 (50) | 6 (46) | 4 (57) | 0.09 |

**Definition of abbreviations:** ARDS = acute respiratory distress syndrome; BMI = body mass index; COVID-19 = coronavirus disease; DAD = diffuse alveolar damage; ECMO = extracorporeal membrane oxygenation; HIV = human immunodeficiency virus; ICU = intensive care unit.

Data are presented as n (%), ratio, or mean (± standard deviation).

*Two-group comparisons were performed between patients with COVID-19 and all controls with non–COVID-19 DAD.

Multigroup comparisons were performed between patients with COVID-19, patients with non-viral DAD, and controls with viral DAD.

The log-rank (Mantel-Cox) test was used to compare the differences in survival distributions of the different subcohorts.

Patients who were not intubated because of goals of care (do-not-intubate [DNI] order) who would have met ARDS criteria once intubated on PEEP and with pathologic evidence consistent with DAD. P values were calculated by Fisher’s exact test, chi-square test, or Mann-Whitney U test.
Figure 3. Semiquantitative premortem radiological phenotyping in COVID-19 by chest CT examinations. (A) Each segment of the five lung lobes was evaluated for dilated segmental or subsegmental vessels and scored on the basis of the distribution of the vessels as follows: 0 = no dilated vessels, 1 = either dilated peripheral or central vessels, 2 = dilated central and peripheral vessels. Axial CT images of the chest obtained at lung-window settings show dilated subsegmental pulmonary vessels (arrows), which are engorged and tortuous. The dilated vessels are located within the periphery of the lung (peripheral 1/3 of the lung; second image from the left), within the center of the lung (central 2/3 of the lung; third image from the left), or in both the periphery and the center (fourth image from the left). Significant differences between patients with COVID-19 and controls with non–COVID-19 DAD were seen in six different lung segments: lower lobe (LLL) lateral basal (p = 0.003), LLL superior (p = 0.05), left upper lobe (LUL) apicoposterior (p = 0.024), right lower lobe (RLL) lateral basal (p = 0.019), RLL superior (p = 0.026), and right upper lobe (RUL) posterior (p = 0.035). (B and C) Vessel distribution score is presented in (B) the heat map and (C) lung diagrams for both groups in (B), the first column represents controls with non–COVID-19 DAD, and the second column represents patients with COVID-19. Each row represents an individual lung segment. The scale bar (thin rectangle, right side) indicates the score values in the heatmap and lung diagrams. Blue denotes the minimum score (0), and salmon denotes the maximum score (2). (D) Mean overall segmental distributions of dilated pulmonary vasculature per patient were significantly different among both groups (blue, non–COVID-19 DAD-controls; salmon, COVID-19; p = 0.001). We calculated the global dilated vessel score by adding all the individual segmental vessel scores in each patient. (E) The global dilated vessel score, which incorporates information on all the lung segments, was significantly higher in patients with COVID-19 when compared with controls with non–COVID-19 DAD (blue, non–COVID-19 DAD; salmon, COVID-19; p = 0.001). The boxes reflect the interquartile range, and the whiskers indicate the range down to the minimum and up to the maximum value. Each individual value as a point is superimposed on the graph. Individual groups were compared using the Mann-Whitney U test.

Patients with COVID-19 were more likely to have superimposed bronchopneumonia than controls with non–viral DAD (p = 0.012; Figure 4B) but not more than controls with viral DAD (p = 0.20). Controls with viral DAD were more likely to show alveolar hemorrhage than COVID-19 (p = 0.035).

Most patients with COVID-19 had at least focal organizing fibrosis (n = 17/20), but established fibrosis attributed to COVID-19 was not seen in any of the cases. COVID-19 lungs showed focal interstitial inflammation (n = 19/20; Figure 4C), and perivascular inflammation (n = 15/20; Figure 4D). The controls with non–COVID-19 DAD showed similar degrees of organizing fibrosis but, overall, less interstitial inflammation (controls with non–viral DAD: p = 0.027; controls with viral DAD: p = 0.039; overall: p = 0.019) and perivascular inflammation (controls with non–viral DAD: P < 0.0001; controls with viral DAD: P = 0.019; overall: P < 0.001).

Microthrombi were identified at least focially in most patients with COVID-19 (n = 19/20). Patients with COVID-19 were more likely to have microthrombi than controls with non–viral DAD (p = 0.03) but
| Histopathologic Characteristics | Patients with COVID-19 (n = 20) | Controls with Non-Viral DAD-Controls (n = 14) | Controls with Viral DAD (n = 7) | P Value * |
|-------------------------------|--------------------------------|----------------------------------------------|-------------------------------|---------|
| Overall assessment, n/n       |                                |                                              |                               |         |
| Diffuse alveolar damage       | 20/20                          | 14/14                                        | 7/7                           |         |
| Acute DAD                     | 3/20                           | 2/14                                         | 3/7                           |         |
| Acute and organizing/fibrosing DAD | 16/20                     | 12/14                                        | 4/7                           | 0.42    |
| Organizing DAD                | 1/20                           | 0/14                                         | 0/7                           |         |
| Microscopic distribution of disease |                            |                                              |                               |         |
| Median number of slides examined, n (range) | 46 (40–50) | 5 (4–12)                                      | 6 (5–10)                      |         |
| Right upper lobe              | 19/20                          | 10/14                                        | 7/7                           |         |
| Right middle lobe             | 19/20                          | 9/14                                         | 7/7                           |         |
| Right lower lobe              | 19/20                          | 5/14                                         | 7/7                           |         |
| Left upper lobe               | 18/20                          | 8/14                                         | 7/7                           |         |
| Left lower lobe               | 18/20                          | 9/14                                         | 6/7                           |         |
| Intra-alveolar processes      |                                |                                              |                               |         |
| Hyaline membranes             |                                |                                              |                               |         |
| None                          | 1/20                           | 0/14                                         | 0/7                           |         |
| Focal/patchy                  | 11/20                          | 7/14                                         | 4/7                           | 0.86    |
| Moderate/extensive            | 8/20                           | 7/14                                         | 3/7                           |         |
| Reactive pneumocytes          |                                |                                              |                               |         |
| None                          | 1/20                           | 2/14                                         | 1/7                           |         |
| Focal/patchy                  | 12/20                          | 6/14                                         | 2/7                           | 0.60    |
| Moderate/extensive            | 7/20                           | 6/14                                         | 4/7                           |         |
| Intra-alveolar giant cells    |                                |                                              |                               |         |
| None                          | 9/20                           | 10/14                                        | 4/7                           |         |
| Focal/patchy                  | 9/20                           | 4/14                                         | 3/7                           | 0.44    |
| Moderate/extensive            | 2/20                           | 0/14                                         | 0/7                           |         |
| Alveolar macrophages          |                                |                                              |                               |         |
| None                          | 1/20                           | 1/14                                         | 1/7                           |         |
| Focal/patchy                  | 6/20                           | 2/14                                         | 4/7                           | 0.25    |
| Moderate/extensive            | 13/20                          | 11/14                                        | 2/7                           |         |
| Alveolar hemorrhage           |                                |                                              |                               |         |
| None                          | 6/20                           | 5/14                                         | 1/7                           |         |
| Focal/patchy                  | 12/20                          | 4/14                                         | 2/7                           | 0.093   |
| Moderate/extensive            | 2/20                           | 5/14                                         | 4/7                           |         |
| Alveolar edema                |                                |                                              |                               |         |
| None                          | 5/20                           | 12/14                                        | 7/7                           |         |
| Focal/patchy                  | 11/20                          | 2/14                                         | 0/7                           | <0.001  |
| Moderate/extensive            | 5/20                           | 0/14                                         | 0/7                           |         |
| Fibrosis                      |                                |                                              |                               |         |
| Organizing fibrosis           |                                |                                              |                               |         |
| None                          | 3/20                           | 2/14                                         | 3/7                           | 0.45    |
| Focal/patchy                  | 12/20                          | 7/14                                         | 2/7                           |         |
| Moderate/extensive            | 5/20                           | 5/14                                         | 2/7                           |         |
| Established fibrosis          |                                |                                              |                               |         |
| None                          | 17/20                          | 12/14                                        | 6/7                           |         |
| Focal/patchy                  | 3/20                            | 2/14                                          | 1/7                                    | 0.99    |
| Moderate/extensive            | 0/20                            | 0/14                                          | 0/7                                    |         |
| Inflammation                  |                                |                                              |                               |         |
| Interstitial                  |                                |                                              |                               |         |
| None                          | 1/20                           | 6/14                                         | 2/7                           | 0.019   |
| Focal/patchy                  | 16/20                          | 7/14                                         | 2/7                           |         |
| Moderate/extensive            | 3/20                           | 1/14                                         | 3/7                           |         |
| Perivascular inflammation     |                                |                                              |                               |         |
| None                          | 5/20                           | 14/14                                        | 6/7                           |         |
| Focal/patchy                  | 14/20                          | 0/14                                         | 1/7                           | <0.001  |
| Moderate/extensive            |                                |                                              |                               |         |
| Vascular alterations          |                                |                                              |                               |         |
| Capillary congestion and CHL  |                                |                                              |                               |         |
| No or limited capillary dilatation | 3/20                  | 7/14                                         | 4/7                           |         |
| Diffuse capillary dilatation ± rare CHL | 12/20            | 7/14                                         | 3/7                           | 0.043†  |
| Diffuse capillary dilatation + multifocal CHL | 5/20          | 0/14                                         | 0/7                           |         |

(Continued)
between interslide-

Figure 5A). No signi-

not in the cartilaginous airways (\( \text{noncartilaginous airways} \)) and in controls with viral DAD (\( P=0.0001 \)) (Figures 5B and 5C).

We then used generalized estimating equations (GEE) to account for repeated measurements of all the intraslide \( C_{\text{Vasc}} \) values determined in patients from the three etiologic groups (patients with COVID-19, controls with non–viral DAD, and controls with viral DAD) within the three different ROI (Table 3). The \( C_{\text{Vasc}} \) of cartilaginous airways in highly congested areas was significantly higher in patients with COVID-19 when compared with controls with non–viral DAD (\( P=0.0024 \)), but not when compared with controls with viral DAD (\( P=0.33 \)). However, in minimally congested areas of the lung, patients with COVID-19 had a significantly lower \( C_{\text{Vasc}} \) of cartilaginous airways when compared with controls with viral DAD (\( P<0.0001 \)), but without statistically significant differences when compared with controls with non–viral DAD (\( P=0.7 \)). The \( C_{\text{Vasc}} \) of noncartilaginous airways in highly congested areas was significantly higher in patients with COVID-19 when compared with non–viral DAD controls (\( P<0.0001 \)) and controls with viral DAD (\( P=0.0095 \)). However, no statistically significant differences in \( C_{\text{Vasc}} \) of noncartilaginous airways were seen between etiologic groups in minimally congested areas (\( P=0.57 \)). When evaluating the alveolar septa, patients with COVID-19 had significantly higher alveolar \( C_{\text{Vasc}} \) in highly congested areas of the lung when compared with controls with non–viral DAD (\( P<0.0001 \)), but not when compared with controls with viral DAD (\( P=0.14 \)). No statistically significant differences in alveolar \( C_{\text{Vasc}} \) were seen between etiologic groups in minimally congested areas of the lung (\( P=0.21 \)).

In patients with COVID-19, there was a significantly increased interslide-alveolar \( \Delta_{\text{Congestion}} \) compared with controls with non–viral DAD and those with viral DAD (non–viral DAD: \( P=0.005 \); viral DAD: \( P=0.002 \); overall: \( P=0.002 \); Figure 5D). No differences in spatial heterogeneity were seen between etiologic groups (Supplemental Results; Figure E10). In patients with COVID-19, the standard deviation of the interslide \( C_{\text{Vasc}} \) was significantly higher in noncartilaginous airways and alveolar septa when compared with the other etiologic groups (Figure E11).

In addition, we performed GEE model analyses to test whether corticosteroid

| histopathologic characteristics | Patients with COVID-19 (\( n=20 \)) | Controls with Non-viral DAD-Controls (\( n=14 \)) | Controls with Viral DAD (\( n=7 \)) | \( P \) value* |
|----------------------------------|-------------------------------------|-----------------------------------------------|--------------------------------|----------------|
| Microthrombi                     |                                      |                                               |                                |                |
| None                             | 1/20                                 | 5/14                                          | 2/7                            | 0.09           |
| Focal/patchy                     | 19/20                                | 8/14                                          | 5/7                            |                |
| Moderate/extensive               | 0/20                                 | 1/14                                          | 0/7                            |                |
| Pulmonary thromboemboli          |                                      |                                               |                                |                |
| None                             | 10/20                                | 14/14                                         | 6/7                            | 0.0038         |
| Focal/patchy                     | 10/20                                | 0/14                                          | 1/7                            |                |
| Moderate/extensive               | 0/20                                 | 0/14                                          | 0/7                            |                |
| Pulmonary infarct                |                                      |                                               |                                |                |
| None                             | 12/20                                | 13/14                                         | 4/7                            | 0.047          |
| Focal/patchy                     | 8/20                                 | 1/14                                          | 2/7                            |                |
| Moderate/extensive               | 0/20                                 | 0/14                                          | 1/7                            |                |
| Other findings                   |                                      |                                               |                                |                |
| Squamous metaplasia              |                                      |                                               |                                |                |
| None                             | 10/20                                | 9/14                                          | 4/7                            | 0.26           |
| Focal/patchy                     | 8/20                                 | 5/14                                          | 1/7                            |                |
| Moderate/extensive               | 2/20                                 | 0/14                                          | 2/7                            |                |
| Bronchopneumonia                 |                                      |                                               |                                |                |
| None                             | 7/20                                 | 12/14                                         | 5/7                            | 0.039          |
| Focal/patchy                     | 10/20                                | 2/14                                          | 1/7                            |                |
| Moderate/extensive               | 3/20                                 | 0/14                                          | 1/7                            |                |

*Definition of abbreviations: CHL = Capillary hemangiomatosis-like changes; COVID-19 = coronavirus disease; DAD = diffuse alveolar damage.

*The focal, established fibrosis is related to pre-existing conditions, including sarcoidosis and smoking-related interstitial fibrosis; not associated with the current disease.

not more than controls with viral DAD (\( P=0.088 \)). Larger pulmonary thromboemboli were also identified (\( n=10/20 \)), often with associated pulmonary infarcts (\( n=8/20 \)). The presence of pulmonary infarcts (Figure 4E), diffuse capillary dilatation with/without capillary hemangiomatosis-like changes (CHL; Figure 4F), and pulmonary thromboemboli (Figure 4G) in patients with COVID-19 was significant compared with its presence in all controls with non–COVID-19 DAD (\( P=0.0038, 0.047, \) and 0.043, respectively) and in controls with non–viral DAD (\( P=0.0016, 0.033, \) and 0.029, respectively), but not in controls with viral DAD (\( P=0.098, 0.22, \) and 0.06, respectively).

Notably, multifocal CHL in multiple sections were only seen in patients with COVID-19.

Microarchitectural Morphometric Analysis

In COVID-19, the mean interslide-\( \text{Max} C_{\text{Vasc}} \) was significantly increased when compared with the mean interslide-\( \text{Min} C_{\text{Vasc}} \) in alveolar septa (\( P<0.0001 \)) and noncartilaginous airways (\( P<0.0001 \)), but not in the cartilaginous airways (\( P=0.27 \); Figure 5A). No significant differences between interslide-\( \text{Max} C_{\text{Vasc}} \) and interslide-\( \text{Min} C_{\text{Vasc}} \) of different ROI were found in other disease entities, except the alveolar-septal compartment in controls with non-viral DAD (\( P<0.0001 \)) (Figures 5B and 5C).

Table 2. (Continued)
treatment would be associated with different morphometric indices of $C_{Vasc}$. Our models did not show any statistically significant effect of corticosteroid use in the $C_{Vasc}$ of the three different compartments (Table E7).

**Association of $C_{Vasc}$ with Histologic Findings**

We also used GEE analyses to account for repeated measurements of all the intraslide $C_{Vasc}$ values determined in patients with COVID-19 to identify associations with histological findings present at the slide level (Table 4). The models evaluated three different parameters of vascular congestion: the mean-intraslide-alveolar $C_{Vasc}$ (average of all alveolar annotations within a single slide of a patient), the intraslide-alveolar $MaxC_{Vasc}$ and the intraslide-alveolar $MinC_{Vasc}$.

Lung injury in each H&E slide was classified into early acute lung injury (ALI; without hyaline membrane formation), acute DAD, acute and organizing DAD, and predominantly organizing DAD. Statistically significant differences in mean intraslide-alveolar $C_{Vasc}$ (Wald test, $P < 0.001$), intraslide-alveolar $MaxC_{Vasc}$ (Wald test, $P < 0.001$), and intraslide-alveolar $MinC_{Vasc}$ (Wald test, $P < 0.001$) were identified among different phases of lung injury. Similarly, we found statistically significant differences in measures of alveolar $C_{Vasc}$ in different phases of lung injury in the controls with DAD (Table E8). Specifically, acute DAD showed significantly lower congestion than ALI (mean intraslide-alveolar $C_{Vasc}$ $P < 0.0001$; intraslide-alveolar $MaxC_{Vasc}$ $P < 0.0001$; intraslide-alveolar $MinC_{Vasc}$ $P < 0.0001$) and higher congestion than organizing DAD (mean-intraslide-alveolar $C_{Vasc}$ $P < 0.0001$; intraslide-alveolar $MaxC_{Vasc}$ $P < 0.0001$; intraslide-alveolar $MinC_{Vasc}$ $P < 0.0001$), but without statistically significant differences in congestion when compared with acute and organizing DAD (mean-intraslide-alveolar $C_{Vasc}$ $P = 0.97$; intraslide-alveolar $MaxC_{Vasc}$ $P = 0.94$; intraslide-alveolar $MinC_{Vasc}$ $P = 0.94$).

When analyzing the relationship between alveolar-septal $C_{Vasc}$ and histologic features found in the vicinity of the slides by GEE analyses, the presence of microthrombi was significantly associated with lower alveolar vascular congestion (mean intraslide-alveolar $C_{Vasc}$ $P = 0.0063$; intraslide-alveolar $MaxC_{Vasc}$ $P = 0.010$, intraslide-alveolar $MinC_{Vasc}$ $P = 0.014$), whereas the presence of CHL ($\geq 3$ foci) was significantly associated with higher alveolar vascular congestion (mean intraslide-alveolar $C_{Vasc}$ $P < 0.0001$; intraslide-alveolar $MaxC_{Vasc}$ $P < 0.0001$; intraslide-alveolar $MinC_{Vasc}$ $P < 0.0001$). We analyzed alveolar $C_{Vasc}$ patterns in association with other histological findings, including the presence of focal bronchopneumonia, numerous intra-alveolar macrophages, and hyaline membranes. However, we did not find any association between the three indices of alveolar $C_{Vasc}$ and those parameters. Of note, a human-blinded classification of the overall vascular congestion in a H&E slide showed a statistically significant association with alveolar $C_{Vasc}$ (mean intraslide-alveolar $C_{Vasc}$ $P < 0.0001$; intraslide-alveolar $MaxC_{Vasc}$ $P < 0.0001$; intraslide-alveolar $MinC_{Vasc}$ $P < 0.0001$) (Table E9). Statistically significant differences in measures of intraslide-alveolar $C_{Vasc}$ were also identified among different lung lobes in patients with COVID-19 (Table E10) and controls with DAD (Table E11).

**Respiratory Mechanics and Gas Exchange**

A total of 27 patients in our cohort met the Berlin Definition for ARDS (7). When analyzing the clinical severity in these patients (using a single cross-sectional datapoint), we did not find statistically significant differences between different
entities within 24 hours of intubation (Table 1).

We analyzed the longitudinal changes in gas-exchange laboratory variables and respiratory mechanics patients with ARDS and who were not treated with extracorporeal membrane oxygenation (n = 25). The cohorts of patients with COVID-19–associated ARDS, non–viral ARDS, and viral ARDS who were not on extracorporeal membrane oxygenation were well balanced, except for the fact that patients with COVID-19–associated ARDS were more likely to have a higher body mass index. Differences in intubation length when comparing the three groups were also noted, but no significant differences between time to death from symptom onset and length of hospital stay were found. No differences in immunosuppression, hypoxemia severity, and treatments were seen (Table E12).

We used GEE analyses to longitudinally assess hourly changes in respiratory mechanics and gas-exchange parameters during the last 72 hours before death in patients with ARDS. Changes among different entities are presented in the online...
supplement (Supplemental Results; Figure E12; and Tables E13–E15). Although the assessments in our cohort were limited because of the small number of each subcohort (10 patients with COVID-19–associated ARDS, 10 patients with non–viral ARDS, and five patients with viral ARDS), PaO2/FIO2 ratios significantly differed between patients with COVID-19–associated ARDS and controls with non–COVID-19 ARDS (non–viral ARDS: \( P = 0.029; \) viral ARDS: \( P < 0.0001 \)). VR differed significantly between patients with COVID-19–associated ARDS and controls with non–COVID-19 ARDS (non–viral ARDS: \( P = 0.0019; \) viral ARDS: \( P = 0.0075 \)). Crs in COVID-19–associated ARDS did not statistically differ from that in non–COVID-19 ARDS (non–viral ARDS: \( P = 0.062; \) viral ARDS: \( P = 0.82 \)). Driving pressure (DP) was significantly higher in non–viral ARDS compared with that in COVID-19–associated ARDS \( (P = 0.0013) \), but no differences were found between COVID-19–associated ARDS and viral–associated ARDS \( (P = 0.44) \). No significant differences in mechanical power (MP) between COVID-19–associated ARDS and non–COVID-19 ARDS were found (non–viral ARDS: \( P = 0.1; \) viral ARDS: \( P = 0.84 \)). There were no significant changes in respiratory mechanics and gas-exchange parameters over time, except for VR and MP, which significantly increased in all ARDS patients \( (P = 0.0024 \) and 0.0054, respectively).

Using Ward’s hierarchical clustering, we identified three clusters of patients with ARDS showing differences in AM-alveolar \( C_{Vasc} \) (Supplemental Results; Figure E13; Table E16). Patients in cluster 1 had the highest AM-alveolar \( C_{Vasc} \), VR, and MP and the shortest time to death from symptom onset \( (P = 0.02) \), but with relatively low DP, preserved Crs, and intermediate values for the PaO2/FIO2 ratio when compared with patients from the other clusters.

### Relationship between \( C_{Vasc} \), VR, and Other Respiratory and Gas-Exchange Parameters

The individual relationship between measured AM-alveolar \( C_{Vasc} \) and VR before death in 25 subjects with ARDS was statistically significant and closely fitted a linear regression \( (R^2 = 0.17) \) (Figure 6A). An ANOVA showed that this relationship was statistically significant \( (P = 0.043) \). Linear regression analyses between AM-alveolar \( C_{Vasc} \) and five other variables (VR, MP, Crs, PaO2/FIO2 ratio, and DP) included in our hierarchical clustering analysis did not show any statistically significant associations (Table E17).

### Association of \( C_{Vasc} \) with Time to Death and Length of Hospital Stay

We stratified all patients on the basis of the median AM-alveolar \( C_{Vasc} \) of the entire cohort \( (median = 21.5%) \). Patients whose individual AM-alveolar \( C_{Vasc} \) was lower than the median AM-alveolar \( C_{Vasc} \) (minimally congested alveolar septa) had a median time to death from symptom onset of 21 days, whereas patients whose AM-alveolar \( C_{Vasc} \) was equal to or greater than the median AM-alveolar \( C_{Vasc} \) (highly congested alveolar septa) had a median time to death from symptom onset of 12 days (log-rank test, \( P = 0.03 \); Figure 6B). Patients with minimally congested alveolar septa had a median length of hospital stay of 15 days, whereas patients with highly congested alveolar septa had a median length of hospital stay of 7 days (log-rank test, \( P = 0.02 \); Figure 6C).

We stratified patients with COVID-19 on the basis of the median AM-alveolar \( C_{Vasc} \) of the COVID-19 cohort \( (median = 25.3%) \). Patients with COVID-19 with minimally congested alveolar septa had a median time to death from symptom onset of 18 days, whereas patients with COVID-19 with highly congested alveolar septa had a median time to death from symptom onset of 9 days (log-rank test \( P = 0.02 \); Figure 6D). Patients with COVID-19 with minimally congested alveolar septa had a median length of hospital stay of 12 days, whereas patients with COVID-19 with highly congested alveolar septa had a median length of hospital stay of 6 days (log-rank test \( P = 0.04 \); Figure 6E).

We also performed Cox proportional hazard model analyses to test whether the association of AM-alveolar \( C_{Vasc} \) and clinical outcomes (time to death and length of hospital stay) would be affected by different clinical variables of the cohort, including age, sex, corticosteroid therapy, and ARDS status. After testing five models that included different combinations of all these variables, the association of AM-alveolar \( C_{Vasc} \) with time to death and length of hospital stay

### Definition of abbreviations: COVID-19 = coronavirus disease; DAD = diffuse alveolar damage; ref = reference.

**\( P < 0.01 \) and *** \( P < 0.001 \).
Villalba, Hilburn, Garlin, et al.: Vascular Congestion in COVID-19 and ARDS

remained essentially unchanged and statistically significant for the entire ARDS cohort but not for the COVID-19 subcohort (Table 5).

Discussion

In this study, we highlighted that the lung pathology of fatal COVID-19 is characterized by distinct lung vascular abnormalities that differentiate the disease from other etiologies of DAD, including increased differential $C_{\text{Vasc}}$ of the alveolar septa, increased peribronchial $C_{\text{Vasc}}$ in highly congested areas, perivascular inflammation, multifocal CHL, pulmonary thromboemboli, and pulmonary infarcts. Furthermore, our morphometric analyses gave evidence of the contribution that vascular alterations (as opposed to overdistension) make to changes in the VR—and, possibly, in $V_d$ in ARDS, regardless of etiology—and identified AM-alveolar $C_{\text{Vasc}}$ as a novel histologic correlate of VR in all cases of ARDS. A histologic review revealed significant differences in the prevalence of histologic findings between patients with COVID-19 and controls with non–COVID-19 DAD. Some of these findings have been reported in other studies (3–5). However, to our knowledge, our semiquantitative assessment involves the most extensive sampling protocol performed in COVID-19 autopsies to date (up to 50 lung sections per autopsy, 10 sections each lobe) and thorough comparison with matched cases of fatal viral and non–viral DAD. These findings suggest that, in comparison with other DAD-causing etiologies, COVID-19 is characterized by significant vascular derangements. Interestingly, we did not find significant differences in alveolar $C_{\text{Vasc}}$ and in the presence of microthrombi between patients with COVID-19 and controls with viral DAD. Therefore, thrombosis may be a common pathophysiologic pathway for pulmonary viral infections (10), although elucidation of specific differences between viral etiologies warrants further investigation.

In addition, we found significant differences in vascular congestion of the vasa vasorum of the conducting airways between patients with COVID-19 and those with other viral infections, which is also regionally different within areas of high or minimal congestion. McGonagle et al. have
Figure 6. Vascular congestion, ventilatory ratio (VR), time to death from symptom onset, and hospital stay. The arithmetic mean $C_{\text{Vasc}}$ in alveolar septa (AM-alveolar $C_{\text{Vasc}}$) tended to mirror the mean VR in each cluster. (A) The individual relationship between measured AM-alveolar $C_{\text{Vasc}}$ and VR in all 25 subjects with ARDS was statistically significant and fitted a linear regression ($P=0.043; R^2 = 0.17$). The slope $\Delta C_{\text{Vasc}}/\Delta$VR was computed as ratio of overall change in $C_{\text{Vasc}}$ to overall change in VR (estimate ± SE) was 7.76 ± 3.6%/(minute ventilation(milliliters/minutes) × PaCO$_2$ (mm Hg)). Singular points are indicated, in color, by the corresponding clusters with differences in AM-alveolar $C_{\text{Vasc}}$ to which the patients belong (red = cluster 1; green = cluster 2; blue = cluster 3; for details, see Supplemental Results; Figure E13). We stratified patients with COVID-19 and all patients of the study into two groups on the basis of the median AM-alveolar $C_{\text{Vasc}}$ of the COVID-19 cohort (median = 25.3%) or the entire cohort (median = 21.5%), respectively: patients with an AM-alveolar $C_{\text{Vasc}}$ less than the median AM-alveolar $C_{\text{Vasc}}$ of the cohort (“minimally congested alveolar septa”) or patients with a mean AM-alveolar $C_{\text{Vasc}}$ equal to or greater than the median AM-alveolar $C_{\text{Vasc}}$ of the cohort (“highly congested alveolar septa”). Differences in time to death from symptom onset and length of hospital stay in patients with COVID-19 or all patients of the study classified as having minimally or highly congested alveolar septa were estimated using the Kaplan-Meier method. The resulting Kaplan-Meier curves were compared using a log-rank test. (B–E) Statistically significant differences in time to death from symptom onset were found when comparing patients with minimally versus highly congested alveolar septa (B) in the entire cohort ($P=0.03$) and (D) in the COVID-19 cohort ($P=0.02$). Differences in length of hospital stay were statistically significant (C) in all patients of the study with minimally versus highly congested alveolar septa ($P=0.02$) but not (E) in patients with COVID-19 ($P=0.4$).

Table 5. Cox Proportional Hazard Models Testing the Association between Categories of AM-alveolar $C_{\text{Vasc}}$ (Patients with Highly or Minimally Congested Alveolar Septa) and Clinical Outcomes (Time to Death from Symptom Onset and Length of Hospital Stay)

| Parameter | Entire Cohort (n = 37) | COVID-19 Subcohort (n = 17) |
|-----------|------------------------|------------------------------|
|           | Hazard Ratio | 95% CI | P Value | Hazard Ratio | 95% CI | P Value |
| Unadjusted|             |        |         |             |        |         |
|            | 0.85 | 2.34 | 1.16–4.73 | 0.018* | 0.28 | 1.32 | 0.37–4.66 | 0.67 |
| Adjusted:  |             |        |         |             |        |         |
| Age and sex| 0.91 | 2.49 | 1.21–5.09 | 0.013* | –0.14 | 0.87 | 0.21–3.67 | 0.85 |
| Age, sex, and corticosteroid use | 0.79 | 2.21 | 1.09–4.51 | 0.029* | –0.24 | 0.79 | 0.17–3.60 | 0.76 |
| Age, sex, and ARDS status | 0.95 | 2.59 | 1.26–5.34 | 0.0097** | –0.12 | 0.89 | 0.19–4.05 | 0.88 |
| Age, sex, corticosteroid use, and ARDS status | 0.87 | 2.39 | 1.15–4.94 | 0.019* | –0.02 | 0.98 | 0.20–4.71 | 0.98 |
| Unadjusted | 0.90 | 2.46 | 1.24–4.88 | 0.0097** | 0.75 | 2.13 | 0.59–7.64 | 0.25 |
| Adjusted:  |             |        |         |             |        |         |
| Age and sex | 1.04 | 2.83 | 1.39–5.75 | 0.0041** | 0.4 | 1.50 | 0.34–6.52 | 0.59 |
| Age, sex, and corticosteroid use | 1.21 | 3.35 | 1.58–7.09 | 0.0016** | 0.67 | 1.96 | 0.39–9.97 | 0.42 |
| Age, sex, and ARDS status | 1.07 | 2.90 | 1.41–5.98 | 0.0038** | 0.51 | 1.66 | 0.35–7.77 | 0.52 |
| Age, sex, corticosteroid use, and ARDS status | 1.21 | 3.35 | 1.58–7.10 | 0.0016** | 0.60 | 1.83 | 0.34–9.69 | 0.48 |

Definition of abbreviations: AM = arithmetic mean; ARDS = acute respiratory distress syndrome; CI = confidence interval; COVID-19 = coronavirus disease.

*P<0.05 and **P<0.01.
hypothesized that other respiratory viruses may show predilection for proximal airway involvement, which can lead to vascular alterations in the vicinity of larger airways (10). In fact, in this study, we demonstrated that non–COVID-19 viral infections showed a significantly higher bronchial C\textsubscript{V\textsubscript{max}} in minimally congested areas when compared with COVID-19, but conversely, COVID-19 showed higher broncholar C\textsubscript{V\textsubscript{max}} in areas of high congestion. The implications of this are uncertain but may have consequences that are not yet understood (11).

Premortem CT scans demonstrated that vascular findings were already present before death. These findings are in line with our postmortem findings. We noted extensive abnormalities in regionally dilated subsegmental pulmonary vessels, showing increased branching and tortuosity on CT imaging. The distribution of dilated vessels was significantly different in patients with COVID-19 and controls with non–COVID-19 DAD, with patients with COVID-19 demonstrating vessel dilatation predominately in the posterior and basilar lungs with both peripheral and nonperipheral distributions. We measured vessel dilatation in a semi-quantitative manner, because software packages that quantify total pulmonary vascular area on chest CT imaging are proprietary and can only be used in a subset of chest CT protocols (e.g., thin-section noncontrast CT). Although our semi-quantitative vessel score may be limited, as it was arbitrarily created, multiple radiological studies without pathological correlation have shown similar results (11–18). Additionally, our GEE analyses of histologic data revealed regional lobar differences in alveolar C\textsubscript{V\textsubscript{max}}, which was decreased in the more anteriorly located right middle lobe and in the left upper lobe, compared with the left lower lobe (Table E10).

The clinical implications of vessel dilatation in COVID-19 are still uncertain. However, these pre- and postmortem regional perfusion abnormalities are consistent with findings from other studies (19, 20) and could be related to improved oxygenation with high PEEP (2) and/or prone positioning in patients with COVID-19 (21, 22). As the response to these therapies is not unique to COVID-19, the improved oxygenation may be mainly due to recruitment (23, 24). However, gravitational forces may also contribute, as pruning has already been shown (to some extent) to decrease ventral moderate-to-severe V\textsubscript{d} and increase dorsal moderate-to-severe V\textsubscript{d} in COVID-19 (19).

In our cohort, patients with COVID-19 had higher scores of mosaic attenuation in areas of apparently normal lung parenchyma (Supplemental Results; Figure E7). Mosaic attenuation can be caused by small vessel pathology or small airway disease with air trapping, and it is commonly regarded as a sign of variable regional perfusion (25). As our study lacks expiratory imaging, we cannot definitively distinguish between these causes. However, other studies have noted the presence of peripheral, segmental, or regional perfusion abnormalities on dual-energy CT in COVID-19 (15–17, 26–29), providing evidence that vascular pathology may play a role in causing the mosaic attenuation patterns that we observed. Moreover, some of these studies have detected perfusion abnormalities in both damaged and apparently normal lung parenchyma, suggesting that vascular alterations in COVID-19 may occur in the entire lung parenchyma (17, 29). Using our machine-learning derived pixel classification, we demonstrated that patients with COVID-19 have an increase in the alveolar-C\textsubscript{V\textsubscript{max}} range (interslide–alveolar Δ\textsubscript{m ventilation}) compared with controls with non–COVID-19 DAD, which might indicate regional changes in perfusion that could correspond to mosaic attenuation on CT imaging.

Physiological dead space is an important predictor of adverse outcomes in patients with ARDS (30). Consistent with prior observations in patients with COVID-19–associated ARDS (19, 31), our longitudinal analysis of the VR before death (used as an estimate for V\textsubscript{d}) suggested a significant increase in all cases of ARDS (Table E14). We demonstrated a novel positive correlation between AM-alveolar C\textsubscript{V\textsubscript{max}} and VR in patients with ARDS (Figure 6), which suggests that premortem vascular alterations in the alveolar septa may have played a key role in the clinical course of patients with severe disease, signaled through an increase in V\textsubscript{d}.

In patients with ARDS due to SARS-CoV-2 infection, increased VR has been observed in patients with elevated D-dimer levels (32), suggesting that direct pulmonary vascular thrombotic dysfunction is mechanistic in the increase in physiological V\textsubscript{d}. However, physiological V\textsubscript{d} may also be increased in ventilator-induced lung injury by excessive application or heterogeneous distribution of PEEP. As we did not find an individual association between MP or DP with AM-alveolar C\textsubscript{V\textsubscript{max}} (Table E17), or longitudinal changes (mean and slope) in MP during the last 72 hours of life between ARDS subgroups, the pathological changes and differences in AM-alveolar C\textsubscript{V\textsubscript{max}} found in this study may not be attributed to differences in mechanical ventilation. Therefore, the association between AM-alveolar C\textsubscript{V\textsubscript{max}} and VR may add detailed mechanistic evidence of the direct association between direct pulmonary vascular dysfunction in ARDS and V\textsubscript{d}.

Furthermore, our hierarchical clustering analysis identified an ARDS cluster with high VR, increased AM-alveolar C\textsubscript{V\textsubscript{max}} and relatively preserved Crs in the setting of low DP, which consisted of patients with COVID-19–associated ARDS and viral-associated ARDS. This cluster showed a statistically significant shorter time to death from symptom onset, highlighting a plausible clinically relevant relationship between increased AM-alveolar C\textsubscript{V\textsubscript{max}} and V\textsubscript{d} regardless of ARDS etiologies. Larger multi-institutional cohorts are needed to validate these findings.

Our study is limited by the fact that we did not measure directly physiological V\textsubscript{d}. However, direct assessment of physiological dead space requires specialized equipment to measure exhaled carbon dioxide (33, 34); consequently, it has been underutilized in the acute clinical setting. Furthermore, the VR has been validated in ARDS cohorts showing an association with adverse clinical outcomes and good correlation with directly measured physiological V\textsubscript{d} (9, 31).

Consistent with prior studies (32, 35), our histological and hierarchical clustering analyses suggested that COVID-19–associated ARDS may not be monolithic in pathobiology. Indeed, patients demonstrated a spectrum of pulmonary pathophenotypes, ranging from predominant pulmonary vascular dysfunction (with relatively higher ventilation to perfusion) to interalveolar filling (with relatively lower ventilation to perfusion). Furthermore, in agreement with Panwar et al. (35), Crs showed a wide range of longitudinal values among all patients with ARDS (Figure E12) and appeared to have a lack of relationship with the degree of hypoxemia (Figure E13).

In our cohort, AM-alveolar C\textsubscript{V\textsubscript{max}} was significantly associated with shorter time to death and length of hospital stay in ARDS. Increases in alveolar C\textsubscript{V\textsubscript{max}} were also seen in the association with earlier stages of lung
injury (ALI and acute DAD) in patients with COVID-19 and in controls with DAD (Tables 4 and E8), suggesting the presence of temporal heterogeneity governing the degree of \( C_{\text{Vasc}} \) in cases of respiratory failure. As the chronology of histological lesions has been related to the duration of ARDS in a prior autopsy cohort (36), it is plausible to think that AM-alveolar \( C_{\text{Vasc}} \) may be tightly related to the phase of lung injury. However, principal-component analyses suggested that the stage of lung injury only contributed to a minimum amount of the variance in our system (Figures E14 and E15), likely because the overall histologic assessment showed that most of our cases had mixed features of acute and organizing DAD. Therefore, the relationship between phase of lung injury and AM-alveolar \( C_{\text{Vasc}} \) deserves further investigation. We found an association of microthrombi with lower intraslide-alveolar \( C_{\text{Vasc}} \). Conversely, CHL were associated with higher values of intraslide-alveolar \( C_{\text{Vasc}} \). As both microthrombi and neovascularization possibly alter the blood flow in the lung microvasculature, the increased incidence of CHL in conjunction with microthrombosis in COVID-19 may be responsible for the differences in vascular congestion. Ackermann et al. have shown a potential role of angiogenesis in COVID-19 when compared with influenza (37). However, further studies are needed to determine whether CHL represent a primary angiogenetic process due to viral infection or compensatory capillary proliferation secondary to microthrombosis.

Important limitations of this study include its single-center observational design, small and selective cohorts, differences in number of H&E-slides evaluated in different disease types, and the retrospective nature contributing to missing data. Furthermore, CT had been used for specific imaging indications, including unexplained clinical worsening per American College of Radiology guidelines, possibly introducing selection bias toward more severe disease. However, we did not find relevant clinical differences in patients who had a CT scan performed compared with those who did not have one (Table E5). In addition, the vascular findings on CT identified in this study have been observed in larger cohorts (12–14, 18) with a range of mild to severe disease.

Additionally, our random tissue sampling technique of the lung (Supplemental Methods) did not include a square grid to obtain samples. As this technique may not be considered systematic (38), it may be subject to an operator-dependent bias. Further, we did not measure total lung volume in our cohort, and measurements of surface areas without normalization for total lung volume are considered subject to bias. However, our novel morphometric index (\( C_{\text{Vasc}} \)) does not describe the absolute surface area occupied by RBC pixels but is rather defined as the proportion of the surface area of the annotated compartment occupied by RBC pixels.

Although only two slides were used for the morphometric analysis to define an individual lung’s interslide variability in each case, these represented the least congested and the most congested lung sections selected by a board-certified pathologist who reviewed all the H&E-stained slides of each autopsy. Three GEE models showed that the human-blinded classification of the overall vascular congestion per slide was significantly associated with different measures of \( C_{\text{Vasc}} \) (Supplemental Results). For instance, in a GEE model evaluating mean intraslide-alveolar \( C_{\text{Vasc}} \), when a slide was classified as highly congested by a pathologist, the mean intraslide-alveolar \( C_{\text{Vasc}} \) was 23.82 times higher when compared with slides classified as minimally congested by a pathologist (\( P < 0.001 \)). Therefore, our morphometric analyses can be considered accurate for the determination of vascular congestion heterogeneity.

We only included cases before the approval of some COVID-19–specific drug therapies (e.g., remdesivir). Therefore, our pathological findings can be considered unconfounded by their pleiotropic effects. Because REMAP-CAP (39) and other studies have suggested that corticosteroids other than dexamethasone are similarly beneficial for COVID-19, we hypothesized that their use could be associated with changes in \( C_{\text{Vasc}} \). Although an association between corticosteroid use and different morphometric indices of \( C_{\text{Vasc}} \) was not seen, our study is inappropriate for this analysis because of its nonrandomized and retrospective nature. Future studies should investigate whether corticosteroid administration may alter the progression of the vasculopathy and vascular congestion in COVID-19 and DAD in general.

### Conclusions

In summary, our detailed clinicopathological, radiological, and morphometric analyses in fatal COVID-19 highlight significant vasculopathy in the lung microarchitecture, including alveolar septal congestion, which is associated with shorter time to death and increased VR. Our study provides objective grounds for future clinical, mechanistic and biomarker-driven work assessing the role that vasculopathy plays in COVID-19, ARDS in general, and pulmonary dead space ventilation.

### Author disclosures

are available with the text of this article at www.atsjournals.org.

### Acknowledgment:

Analysis of patient autopsy material was reviewed and approved by the Partners Human Research IRB (Protocol #: 2020P001146).

### References

1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020;324:782–793.
2. Berlin DA, Gužick RM, Martínez FJ. Severe Covid-19. N Engl J Med 2020; 383:2451–2460.
3. Hariri LP, North CM, Shih AR, Israel RA, Maley JH, Villaiba JA, et al. Lung histopathology in coronavirus disease 2019 as compared with severe acute respiratory syndrome and H1N1 influenza: a systematic review. Chest 2021;159:73–84.
4. Satturwar S, Fowkes M, Farver C, Wilson AM, Eccher A, Girolami I, et al. Postmortem findings associated with SARS-CoV-2: systematic review and meta-analysis. Am J Surg Pathol 2021;45:587–603.
5. Konopka KE, Nguyen T, Jentzen JM, Rayes O, Schmidt CJ, Wilson AM, et al. Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 infection is morphologically indistinguishable from other causes of DAD. Histopathology 2020;77:570–578.
6. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep 2017;7:16878.
13. Patel BV, Arachchilage DJ, Ridge CA, Bianchi P, Doyle JF, Garfield B, Zarantonello F, Andreatta G, Sella N, Navalesi P. Prone position and lung ventilation and perfusion matching in acute respiratory failure due to COVID-19. *Am J Respir Crit Care Med* 2020;8:878.

19. Perier F, Tuffet S, Maraffi T, Alcala G, Victor M, Haudebourg AF, et al. Estimated dead space fraction assessed by electrical impedance tomography. *Crit Care* 2020;8:1297–1299.

24. Brunin Y, Despres C, Pili-Floury S, Besch G. Lung recruiting effect of prone positioning in spontaneously breathing patients with COVID-19 assessed by electrical impedance tomography. *Am J Respir Crit Care Med* 2021;204:476–477.

25. Worthy SA, Muller NL, Hartman TE, Swensen SJ, Padley SP, Hansell DM. Mosaic attenuation pattern on thin-section CT scans of the lung: differentiation among infiltrative lung, airway, and vascular diseases as a cause. *Radiology* 1997;205:465–470.

26. Lang M, Som A, Mendoza DP, Flores EJ, Reid N, Carey D, et al. Hypoxemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT. *Lancet Infect Dis* 2020;20:1365–1366.

27. Som A, Lang M, Little B. Pulmonary vascular pathology in Covid-19. *N Engl J Med* 2020;383:887.

28. Si-Mohamed S, Chebib N, Sigovan M, Zumbihl L, Turquier S, Boccalini S, et al. In vivo demonstration of pulmonary microvascular involvement in COVID-19 using dual-energy computed tomography. *Eur Respir J* 2020;56:2002608.

29. Santamarina MG, Boisier Rascal D, Beddings I, Contreras R, Baque M, Volpaccio M, et al. COVID-19: what iodine maps from Perfusion CT can reveal—a prospective cohort study. *Circ Res* 2020;24:619.

30. Nuckton TJ, Alonso JA, Kaillet RH, Daniel BM, Pittet JF, Eisner MD, et al. Pulmonary vascular and perfusion abnormalities on thoracic CT for diagnosis and differential diagnosis of COVID-19: a systematic review and meta-analysis. *Ann Transl Med* 2020;8:878.

31. Liu X, Liu X, Xu Y, Xu Z, Huang Y, Chen S, et al. Ventilatory ratio in hypercapnic mechanically ventilated patients with COVID-19–associated acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2020;201:1297–1299.

32. Grasselli G, Tonelli T, Protti A, Langer T, Girardis M, Bellani G, et al; collaborators. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. *Lancet Respir Med* 2020;8:1201–1208.

33. Raymond LW. The alveolar air equation abbreviated. *Chest* 1978;74:675–676.

34. Morales-Quinteros L, Schultz MJ, Bringuier C, Despres C, Pili-Floury S, Besch G, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19 pneumonia. *Radiol Cardiothorac Imaging* 2020;2:e200277.

35. Parw W, Madotto F, Lafay JG, van Haren FMP. Compliance phenotypes in early acute respiratory distress syndrome before the COVID-19 pandemic. *Am J Respir Crit Care Med* 2020;202:1244–1252.

36. Thille AW, Esteban A, Fernández-Segoviano P, Rodríguez JM, Aramburu JA, Vargas-Erazuriz P, et al. Chronicity of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies. *Lancet Respir Med* 2013;1:395–401.

37. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. The bronchial circulation in COVID-19 pneumonia. *Lancet Infect Dis* 2020;20:1252.

38. Thille AW, Esteban A, Fernández-Segoviano P, Rodríguez JM, Aramburu JA, Vargas-Erazuriz P, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. *N Engl J Med* 2020;383:120–128.

39. Haia CC, Hyde DM, Ochs M, Weibel ER; ATS/ERS Joint Task Force on the acute respiratory distress syndrome. The alveolar air equation abbreviated. *JAMA* 2012;307:2526–2533.

40. Gagnon C, Reignier J, Richard JC, Beaurel P, Gacouin A, Boulain T, et al.; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med* 2013;368:2159–2168.

41. Brunin Y, Despres C, Pili-Floury S, Besch G. Lung recruiting effect of prone positioning in spontaneously breathing patients with COVID-19 assessed by electrical impedance tomography. *Am J Respir Crit Care Med* 2021;204:476–477.

42. Worthy SA, Muller NL, Hartman TE, Swensen SJ, Padley SP, Hansell DM. Mosaic attenuation pattern on thin-section CT scans of the lung: differentiation among infiltrative lung, airway, and vascular diseases as a cause. *Radiology* 1997;205:465–470.

43. Lang M, Som A, Mendoza DP, Flores EJ, Reid N, Carey D, et al. Hypoxemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT. *Lancet Infect Dis* 2020;20:1365–1366.

44. Som A, Lang M, Little B. Pulmonary vascular pathology in Covid-19. *N Engl J Med* 2020;383:887.

45. Si-Mohamed S, Chebib N, Sigovan M, Zumbihl L, Turquier S, Boccalini S, et al. In vivo demonstration of pulmonary microvascular involvement in COVID-19 using dual-energy computed tomography. *Eur Respir J* 2020;56:2002608.

46. Santamarina MG, Boisier Rascal D, Beddings I, Contreras R, Baque M, Volpaccio M, et al. COVID-19: what iodine maps from Perfusion CT can reveal—a prospective cohort study. *Circ Res* 2020;24:619.

47. Nuckton TJ, Alonso JA, Kaillet RH, Daniel BM, Pittet JF, Eisner MD, et al. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. *N Engl J Med* 2002;346:1281–1286.

48. Liu X, Liu X, Xu Y, Xu Z, Huang Y, Chen S, et al. Ventilatory ratio in hypercapnic mechanically ventilated patients with COVID-19–associated acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2020;201:1297–1299.

49. Grasselli G, Tonelli T, Protti A, Langer T, Girardis M, Bellani G, et al; collaborators. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. *Lancet Respir Med* 2020;8:1201–1208.

50. Raymond LW. The alveolar air equation abbreviated. *Chest* 1978;74:675–676.

51. Morales-Quinteros L, Schultz MJ, Bringuier C, Despres C, Pili-Floury S, Besch G, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19 pneumonia. *Radiol Cardiothorac Imaging* 2020;2:e200277.

52. Parw W, Madotto F, Lafay JG, van Haren FMP. Compliance phenotypes in early acute respiratory distress syndrome before the COVID-19 pandemic. *Am J Respir Crit Care Med* 2020;202:1244–1252.

53. Thille AW, Esteban A, Fernández-Segoviano P, Rodríguez JM, Aramburu JA, Vargas-Erazuriz P, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. *N Engl J Med* 2020;383:120–128.

54. Haia CC, Hyde DM, Ochs M, Weibel ER; ATS/ERS Joint Task Force on the acute respiratory distress syndrome. The alveolar air equation abbreviated. *JAMA* 2012;307:2526–2533.

55. Gagnon C, Reignier J, Richard JC, Beaurel P, Gacouin A, Boulain T, et al.; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med* 2013;368:2159–2168.